Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.